IRIS
LAPUCCI, CATERINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 4.834
AS - Asia 63
NA - Nord America 2
AF - Africa 1
SA - Sud America 1
Totale 4.901
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 4.834
CN - Cina 58
SG - Singapore 5
US - Stati Uniti d'America 2
BR - Brasile 1
KE - Kenya 1
Totale 4.901
Salva come PNG Salva come JPEG
Città #
Genoa 2.547
Genova 1.276
Vado Ligure 614
Rapallo 383
Beijing 28
Bordighera 10
Singapore 4
Ashburn 2
Rome 2
Nairobi 1
Nova Petrópolis 1
Totale 4.868
Salva come PNG Salva come JPEG
Nome #
Different MRI patterns in MS worsening after stopping fingolimod 171
Osteopathic Manipulative Therapy and Multiple Sclerosis: A Proof-of-Concept Study 169
Molecular imaging of multiple sclerosis: from the clinical demand to novel radiotracers 164
123I-FP-CIT SPECT validation of nigro-putaminal MRI tractography in dementia with Lewy bodies 152
Relationship between retinal inner nuclear layer, age, and disease activity in progressive MS 150
"Limbic encephalitis with acute onset and Hu antibodies treated with rituximab: Paraneoplastic or non-paraneoplastic disorder?" 142
Degree of microstructural changes within T1-SE versus T1-GE hypointense lesions in multiple sclerosis: relevance for the definition of “black holes” 138
How much do periventricular lesions assist in distinguishing migraine with aura from CIS? 131
Serum sickness (Like Reaction) in a patient treated with alemtuzumab for multiple sclerosis: A case report 125
Could arterial spin labelling perfusion imaging uncover the invisible in N-methyl-d-aspartate receptor encephalitis? 122
A longitudinal clinical and MRI evaluation of the treatment with erenumab 116
Embracing resilience in multiple sclerosis: a new perspective from COVID-19 pandemic 110
No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study 108
Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy 106
Effects of aging on finger movements in multiple sclerosis 104
Aggressive multiple sclerosis: a single-centre, real-world treatment experience with autologous haematopoietic stem cell transplantation and alemtuzumab 103
Fingolimod and Dimethyl-Fumarate-Derived Lymphopenia is not Associated with Short-Term Treatment Response and Risk of Infections in a Real-Life MS Population 103
Neuroimaging Findings in Mild Cognitive Impairment 101
Assessing upper limb function in Multiple Sclerosis by an engineered glove 100
Impact of treatment on cellular immunophenotype in MS: A cross-sectional study 97
The early effect of cladribrine versus fingolimod on clinical and MRI measures in relapsing remitting multiple sclerosis 93
Outcomes after fingolimod to alemtuzumab treatment shift in relapsing-remitting MS patients: a multicentre cohort study 92
Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies 89
Two-way crossed cerebellar diaschisis in a clinically isolated syndrome suggestive of multiple sclerosis 85
Impact of Natural Killer (NK) Cells on Immune Reconstitution, and Their Potential as a Biomarker of Disease Activity, in Alemtuzumab-Treated Patients with Relapsing Remitting Multiple Sclerosis: An Observational Study 85
Clinical and radiological correlates of apathy in multiple sclerosis 82
Subgroup comparison according to clinical phenotype and serostatus in autoimmune encephalitis: a multicenter retrospective study 82
Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-Remitting Multiple Sclerosis 78
In-vivo characterization of macro- and microstructural injury of the subventricular zone in relapsing-remitting and progressive multiple sclerosis 75
CD19+ B cell values predict the increase of anti-SARS CoV2 antibodies in fingolimod-treated and COVID-19-vaccinated patients with multiple sclerosis 72
Brain FDG-PET findings in chimeric antigen receptor T-cell therapy neurotoxicity for diffuse large B-cell lymphoma 72
Central vein sign and diffusion MRI differentiate microstructural features within white matter lesions of multiple sclerosis patients with comorbidities 72
Sex differences in neuroimaging biomarkers in healthy subjects and dementia 69
Predictors of Ocrelizumab Effectiveness in Patients with Multiple Sclerosis 68
ADVANCED SUSCEPTIBILITY AND DIFFUSION WEIGHTED IMAGING IN THE DIAGNOSIS OF MULTIPLE SCLEROSIS: FROM RESEARCH TO CLINICAL APPLICATIONS 68
Tailoring B cell depletion therapy in MS according to memory B cell monitoring 67
Cognitive changes in patients with relapse-free MS treated with high efficacy therapies: the predictive value of paramagnetic rim lesions 66
A real-world study of alemtuzumab in a cohort of Italian patients 65
Personalizing ocrelizumab treatment in Multiple Sclerosis: What can we learn from Sars-Cov2 pandemic? 63
Relationship Between Retinal Layer Thickness and Disability Worsening in Relapsing-Remitting and Progressive Multiple Sclerosis 62
The effect of Cladribine and Fingolimod treatments on retinal atrophy 61
Evaluating the central vein sign in paediatric-onset multiple sclerosis: A case series study 61
Effect of ocrelizumab treatment on retinal atrophy: preliminary results from a single-center observational study 60
Effect of SARS-CoV-2 vaccination on natural killer cell responses in multiple sclerosis 54
Mapping tissue microstructure across the human brain on a clinical scanner with soma and neurite density image metrics 52
Improved detection of multiple sclerosis lesions with T2-prepared double inversion recovery at 3T 51
Neuromuscular complications following targeted therapy in cancer patients: beyond the immune checkpoint inhibitors. Case reports and review of the literature 50
Brain lesion microstructure in neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein disease 49
Rapidly ascending necrotizing myelopathy with widespread brain white matter involvement following intrathecal methotrexate and cytosine arabinoside treatment in an adult with T cell acute lymphoblastic leukemia 48
The role of disconnection in explaining disability in multiple sclerosis 46
Cortical ischemic lesions from atrial myxoma as a mimic of disease activity in an RRMS antiCD20-treated patient 41
null 41
Lesion phenotyping based on magnetic susceptibility in pediatric multiple sclerosis 40
Multiparametric Characterization and Spatial Distribution of Different MS Lesion Phenotypes 39
Safety of anti-varicella zoster virus vaccination in patients with multiple sclerosis treated with natalizumab: A case series 38
A real-world study of Alemtuzumab in a cohort of Italian patients 37
Vaccinations in patients with multiple sclerosis: a real-world, single-center, experience 36
Ocrelizumab in MS patients with persistence of disease activity after alemtuzumab: A multi-center Italian study 36
Coagulation activation and cerebral hypoperfusion in relapsing-remitting multiple sclerosis 34
Vaccinations in patients with multiple sclerosis: a real-world, single-center experience 34
Effect of SARS-CoV-2 mRNA vaccination in multiple sclerosis patients treated with disease modifying therapies 28
Tissue factor as a potential coagulative/vascular marker in relapsing-remitting multiple sclerosis 25
Multicenter Evaluation of AI-generated DIR and PSIR for Cortical and Juxtacortical Multiple Sclerosis Lesion Detection 24
The “central vein sign” to differentiate multiple sclerosis frommigraine 21
null 20
E200k familial creutzfeldt-jakob disease presenting with subacute multiple cranial neuropathy 10
The early effect of induction versus continuous therapies in active multiple sclerosis: a multimodal study on the first course of cladribine versus fingolimod 8
Totale 5.061
Salva come PNG Salva come JPEG
Categoria #
all - tutte 22.097
article - articoli 21.007
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 799
Totale 43.903
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021265 0 0 0 62 49 32 13 22 22 38 15 12
2021/2022339 21 4 12 28 21 30 12 72 27 43 19 50
2022/2023480 43 50 10 47 50 68 7 29 66 14 74 22
2023/2024626 24 42 18 76 35 83 122 37 30 18 36 105
2024/20251.714 105 113 72 90 196 153 155 307 97 97 187 142
2025/2026877 393 73 201 210 0 0 0 0 0 0 0 0
Totale 5.061